Testing Market size is USD 2.24 Billion in 2025 and is expected to reach USD 6.66 Billion by 2035 due to the increasing adoption of NIPTAustin, March 10, 2026 (GLOBE NEWSWIRE) -- According to SNS ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Please provide your email address to receive an email when new articles are posted on . Biopsies with high donor-derived cell-free DNA levels were likely to reveal antibody-mediated rejection.

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...

Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT. The impact of the use of hypomethylating agents ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? — M.N. Answer: When screening patients ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for ...